Loading...
•
Dec 31, 2019
Gilead Sciences Q4 2019 Earnings Report
Gilead Sciences' financial results for Q4 2019 were announced, with total revenues of $5.9 billion and diluted EPS of $2.12.
Key Takeaways
Gilead Sciences announced its Q4 and full year 2019 financial results. The total revenues for the fourth quarter of 2019 were $5.9 billion, and the net income was $2.7 billion, or $2.12 per diluted share.
Fourth Quarter Product Sales reached $5.8 billion.
Full Year 2019 Product Sales amounted to $22.1 billion.
Full Year 2019 Diluted EPS was $4.22 per share.
Full Year 2019 Non-GAAP Diluted EPS was $6.63 per share.
Gilead Sciences
Gilead Sciences
Gilead Sciences Revenue by Segment
Gilead Sciences Revenue by Geographic Location
Revenue by Segment
HIV Revenue
CapyFin.comHCV products Revenue
CapyFin.comYescarta Revenue
CapyFin.comOther product sales Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Gilead provided full year 2020 guidance, projecting product sales between $21.8 billion and $22.2 billion and diluted EPS between $6.05 and $6.45.
Positive Outlook
- Product Sales: $21,800 - $22,200 million
- Non-GAAP Product Gross Margin: 86% - 87%
- R&D Expenses: Mid-single digit percentage growth
- SG&A Expenses: Mid-single digit percentage growth
- Operating Income: $10,100 - $10,800 million
Challenges Ahead
- Effective Tax Rate: ~21%
- Diluted EPS: $6.05 - $6.45
- GAAP Diluted EPS: $5.15 - $5.55
Revenue & Expenses
Visualization of income flow from segment revenue to net income